Table 2.
MMTV breast cancer case control studies. S = significant. Ns = not significant
| Study | Country | Method | Breast cancer | Breast control | Significance |
|---|---|---|---|---|---|
| Axel 1972 [20] | US | Molecular hybridisation | 19/29 66% | 0/15 0% | 0.004 s |
| Mesa-Tajada 1978 [30] | US | IHC | 15/131 39% | 0/18 0% | 0.001s |
| Wang 1995 [23] | US | PCR | 121/314 38.5% | 2/107 2% | 0.001s |
| Etkind 2000 [31] | US | PCR | 27/73 37% | 0/35 0% | 0.001s |
| Melana 2001 [32] | US | PCR | 32/106 30% | 1/106 1% | 0.001s |
| Melana 2002 [33] | Argentina | PCR | 23/74 31% | 1/10 10% | 0.003s |
| Ford 2003 [24] | Australia | PCR | 19/45 42% | 2/111 2% | 0.001s |
| Ford 2004 [34] | Australia | PCR | 45/144 31% | 0/111 0% | 0.001s |
| Zammarchi 2006 [25] | Italy | PCR | 15/45 33% | 0/8 0% | 0.008 s |
| Hachana 2008 [35] | Tunisia | PCR | 17/122 14% | 0/122 0% | 0.001s |
| Lawson 2010 [36] | Australia | In situ PCR | 33/74 45% | 0/29 0% | 0.001s |
| Mazzanti 2011 [29] | Italy | PCR | 47/69 68% | 0/20 0% | 0.001s |
| Glenn 2012 [37] | Australia | PCR | 39/50 78% | 13/40 33% | 0.045 s |
| Slaoui 2014 [38] | Morocco | PCR | 24/42 57% | 6/18 33% | 0.312 ns |
| Cedro-Tanda 2014 [39] | Mexico | PCR | 57/458 12% | 72/458 16% | 0.308 ns |
| Naushad 2014 [40] | Pakistan | PCR | 83/250 29% | 0/15 0% | 0.001s |
| Reza 2015 [41] | Iran | PCR | 12/100 12% | 0/100 0% | 0.001s |
| Shariatpanahi 2017 [42] | Iran | PCR | 19/59 32% | 3/59 5% | 0.002 s |
| Al Dossary 2018 [43] | Saudi Arabia | PCR | 6/101 6% | 0/51 0% | 0.082 ns |
| Seo 2019 [44] | Korea | PCR | 12/128 9% | 0/128 0% | 0.013 s |
| Al Hamad 2020 [45] | Jordan | PCR | 11/100 11% | 0/20 0% | 0.023 s |
| Loutfy 2021 [46] | Egypt | PCR | 38/50 76% | 0/10 0% | 0.001s |
| Wang 2021 [5] | China | PCR | 21/119 18% | 2/50 4% | 0.05 s |
| Khalid 2021 [47] | Pakistan | PCR | 69/105 66% | 2/15 13% | 0.023 s |
| Gupta 2021 [48] | Croatia | PCR | 5/70 7% | 0/16 0% | 0.056 ns |
| Gupta 2022 [49] | Qatar | PCR | 11/74 15% | 0/14 0% | 0.001s |